Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points.
Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y).
Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so. And the United States (US) market would see a 4 per cent decline quarter-on-quarter (Q-o-Q) on lower generic Revlimid (cancer drug) and steady low mid-single digit price erosion.
Sun Pharmaceutical Industries has seen traction in specialty, brokerages said, while Alkem and Lupin had recent launches in the US market.
Nuvama Institutional Equities said the pharma universe would report 11 per cent revenue growth, a 17 per cent Ebitda increase, and a 19 per cent expansion in profit after tax (PAT). The Ebitda margin is expected to go up 131 basis points Y-o-Y.
Denne historien er fra October 14, 2024-utgaven av Business Standard.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra October 14, 2024-utgaven av Business Standard.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Ratan Tata: Picture perfect
Politeness is to human nature What Warmth is to Wax.
I chose DLF over Disneyland dream, says KP Singh
KP SPEAK: Gurugram remains a developing city; urban planning needs a long-term vision, the PM must set up a high-powered panel for it
REDISCOVERY OF INDIA
Indian collectors are reclaiming Colonial-era art created by foreigners as an intrinsic part ofthe country's history
Go for fund with large AUM, high credit quality and low cost
Liquid funds have offered an average return of 7.28 per cent over the past year.
Auto majors in slow lane on weak demand
TaMo, Maruti, SMIL stocks down up to 23% in 4 weeks; analysts say downside risk limited, an opportunity for long-term investors
Volume growth for NMDC to remain robust in H2FY25
NMDC's revenue in Q2FY25 came in at ₹4,900 crore (a rise of 23 per cent year-on-year or Y-o-Y), while it was down 9 per cent quarter-on-quarter (Q-o-Q).
CIEL HR to file draft papers for ₹450 cr IPO
CIEL HR Services (CIEL), which uses technology to provide human resources solutions, will soon file draft papers for an initial public offering (IPO) estimated to be around ₹450 crore in size, according to sources.
Angel funds see red in Sebi's new accredited investors-only proposal
The Securities and Exchange Board of India's (Sebi's) proposal to allow only \"accredited investors\" to invest in angel funds has raised concerns in some quarters, even as most fund managers believe the overall ecosystem was set for a boost.
CLSA does U-turn on China, ups India exposure after Trump win
Says India seen as more attractive investment destination due to its strong economic growth and relatively low exposure to trade risks
Unfazed by mkt fall, largecap, flexicap MF schemes shine in Oct
Both categories saw all-time-high inflows during the month
